Myelodysplastic Syndrome with Transfusion Dependence Treated with Venetoclax
Myelodysplastic syndromes are characterized by ineffective hematopoiesis in one or more lineages of the bone marrow. They are a group of heterogeneous clonal stem cell malignancies with a high risk to progress to acute myeloid leukemia. Currently, there are no curative FDA-approved medications for m...
Main Authors: | Waqas Jehangir, Alexander Karabachev, Taimoor Jahangir, Elvira Umyarova |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2020-01-01
|
Series: | Case Reports in Hematology |
Online Access: | http://dx.doi.org/10.1155/2020/9031067 |
Similar Items
-
Pulmonary Haemosiderosis Secondary to Hereditary Haemochromatosis; a Case Report
by: Waqas Jehangir, et al.
Published: (2020-01-01) -
Advances in Treatment of Transfusion-dependent Lower-risk Myelodysplastic Syndromes
by: FENG Yue, et al.
Published: (2021-04-01) -
Rapidly Progressive Pancreatic Lipomatosis in a Young Adult Patient with Transfusion-dependent Myelodysplastic Syndrome
by: Wei-Ching Lin, et al.
Published: (2007-08-01) -
Transfusion Thresholds, Quality of Life, and Current Approaches in Myelodysplastic Syndromes
by: Ioannis Koutsavlis
Published: (2016-01-01) -
Refractory Autoimmune Cytopenias Treated With Venetoclax
by: Max J. Gordon, et al.
Published: (2019-06-01)